Treats Parkinson’s disease. ANDA 214495, held by Macleods Pharms. Carbidopa; Entacapone; Levodopa.
As of Nov 16, 2026, ANDA 214495 (Carbidopa, Levodopa And Entacapone), held by Macleods Pharms, was first approved by FDA on Apr 15, 2025, with 1 approved supplement and 0 published complete response letters.
Carbidopa, levodopa and entacapone tablets, is indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets can be used: To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2025 | Original application | Approved | None posted |
| Carbidopa, Levodopa And Entacapone12.5MG;200MG;50MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Carbidopa, Levodopa And Entacapone18.75MG;200MG;75MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Carbidopa, Levodopa And Entacapone25MG;200MG;100MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Carbidopa, Levodopa And Entacapone31.25MG;200MG;125MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Carbidopa, Levodopa And Entacapone37.5MG;200MG;150MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Carbidopa, Levodopa And Entacapone50MG;200MG;200MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Rx |
| Nov 2, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 15, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters